Drug Profile

PBF 677

Alternative Names: PBF-677

Latest Information Update: 24 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Palobiofarma
Class Anti-inflammatories; Eye disorder therapies; Irritable bowel syndrome therapies; Small molecules
Mechanism of Action Adenosine A3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Ulcerative colitis
Discontinued Glaucoma; Irritable bowel syndrome

Most Recent Events

24 Jan 2022 Discontinued - Phase-I for Glaucoma (In volunteers) in Spain (PO) (Palobiofarma pipeline, January 2022)
24 Jan 2022 Discontinued - Phase-I for Irritable bowel syndrome in Spain (PO) (Palobiofarma pipeline, January 2022)
28 Oct 2019 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in Spain (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com